Beckman Coulter Showcases New Prostate Cancer Blood Test at 2014 AUA Annual Meeting

Beckman Coulter Diagnostics, a leader in prostate cancer testing will demonstrate its dedication to advancing healthcare for patients and physicians at the 2014 American Urological Association (AUA) Annual Meeting in Orlando, Fla., May 16-21, 2014. The Beckman Coulter exhibition booth (#1511) will showcase the new, nationally available Prostate Health Index (phi)*, a simple blood test that is three times more specific for the detection of prostate cancer than PSA alone.

A patient's phi score gives more accurate information about what an elevated PSA level might mean and the probability of finding prostate cancer on biopsy.* Beckman Coulter's phi test fills the diagnostic gap between PSA screening and a prostate biopsy.

The phi test is now available to physicians nationwide through Innovative Diagnostics Laboratory (IDL), a national clinical reference laboratory specializing in personalized blood-based testing to find, understand and treat cancer.

In addition to the exhibition booth, Beckman Coulter is hosting the following events:

ICU Theater
"The Prostate Health Index (phi) Now Available: U.S. Physician Clinical Update"
Dr. William Catalona and Stacy Loeb, M.D.
Sunday, May 18, 10 a.m.

Poster Presentations
Tumour volume estimation from preoperative measurement of prostate volume and serum and urine biomarkers
Abstract: MP63-06
Mathieu Roumiguie, Léonor Nogueira, Jean Baptiste Beauval, Xavier Gamé, Michel Soulié, Pascal Rischmann, Bernard Malavaud, TOULOUSE, France
Monday, May 19, 2014 10:30 a.m.-12:30 p.m.
OCCC: W 304 A

[-2]proPSA for prediction of early biochemical recurrence after radical prostatectomy: preliminary results from an observational cohort study
Abstract MP63-06
Massimo Lazzeri, Ferruccio Ceriotti, NicolòMaria Buffi, Giovanni Lughezzani, Alessandro Larcher, Nicola Fossati, et al.
Monday, May 19, 2014 3:30 p.m.-5:30 p.m.
OCCC: W 307
This presentation has been selected for the AUA Press Event Program on Monday, May 19 at 10:30 a.m.

p2PSA and derivatives (%p2PSA and PHI) accurately predict prostate cancer in obese men from a multicenter prospective European study
Abstract: MP74-09
Alberto Abrate, Massimo Lazzeri, Nicolòmaria Buffi, Alexander Haese, Alexandre de la Taille, Thomas McNicholas, Stevenag, et al.
Tuesday, May 20, 2014 1 p.m.-3 p.m.
OCCC: W 304 E

External validation of a prostate health index (phi) based nomogram for predicting prostate cancer at extended biopsy in a European multicenter population
Abstract MP74-12
Giovanni Lughezzani, Massimo Lazzeri, Alexander Haese, Thomas McNicholas, Stevenag, Alexandre de la Taille, et al.
Tuesday, May 20, 2014 1 p.m.-3 p.m.
OCCC: W 304 E

Visitors to Beckman Coulter's booth will have opportunities to learn from industry experts how the company's latest diagnostic prostate cancer innovation is enabling physicians with better knowledge and greater confidence in patient care.

* The Prostate Health Index is indicated for use as an aid in distinguishing prostate cancer from benign prostatic conditions, for prostate cancer detection in men aged 50 years and older with total PSA ≥ 4.0 to ≤ 10.0 ng/mL, and with digital rectal examination findings that are not suspicious for cancer. Prostatic biopsy is required for diagnosis of cancer.